A PYMNTS Company

US: Biopharmaceutical merger announced

By  |  March 8, 2015

Winston-Salem-based Targacept plans to merge with Catalyst Biosciences Inc., a privately held biopharmaceutical company based in San Francisco.

If approved by regulators and shareholders, operations will be absorbed by Catalyst Bioscience in San Francisco, ending Targacept’s 15 year run in Winston-Salem.

The focus of the merger will be to use engineered human proteases to develop next-generation biopharmaceuticals with an improved efficacy and therapeutic index to treat major diseases.

 

Full Content: GEN

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.